Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Ocrelizumab real-world safety in the treatment of multiple sclerosis (MS): Differences between investigator-reported and patient-reported safety
Multiple Sclerosis
P6 - Poster Session 6 (12:00 PM-1:00 PM)
9-021

Both from the authorities and from the neurological community it is a matter of ongoing discussion, whether and to what extent investigator vs. patient-reported safety issues differ.

CONFIDENCE (EUPAS22951) is an open phase IV study, systematically collecting investigator-reported clinical data of ocrelizumab-treated patients.

PSPs such as “TrotzMS” accompany patients during lifelong MS therapy regardless of treatment. As part of the standard pharmacovigilance procedure, unsystematically reported safety data from patients of PSPs are captured.

To contrast investigator-reported safety of ocrelizumab captured by the NI-PASS CONFIDENCE with patient-reported safety from the patient support program (PSP) “TrotzMS”.

CONFIDENCE: Adverse events (AEs) will be collected during the observation period starting from the first administration of ocrelizumab.

“TrotzMS” PSP: AEs reported freely by patients will be collected during regular consultations.

Updated safety data from both programs will be presented.

CONFIDENCE: Since April 2018, 1624 patients newly treated with ocrelizumab have been enrolled. Preliminary data as of 30 September 2019 show that approximately 80.0% were diagnosed with RMS and 20.0% with PPMS. Mean age at initiation of ocrelizumab therapy was 56 years (range 18–72), with a majority of female patients (64.0%). 55.1% of patients have experienced at least one AE. The most common AEs were infections and infestations, followed by nervous system disorders, general disorders and administration site conditions. Incidences of infections and serious infections were within expected ranges.

“TrotzMS” PSP: Since January 2018, approximately 536 ocrelizumab-treated patients have joined the PSP. 512 AEs were documented. Patients primarily reported disease-related symptoms such as nervous system disorders and infections. As safety data were captured unsystematically, calculations of incidences was not possible.

No new or unexpected safety-signals were observed in either program.

Patients and physicians have a different perception of safety. Both perspectives should be considered when describing the safety profile and optimizing MS treatment.

Authors/Disclosures
Jost Leemhuis
PRESENTER
Jost Leemhuis has received personal compensation for serving as an employee of Roche Pharma AG.
Richard W. Hughes, MBBS (Biogen) Dr. Hughes has received personal compensation for serving as an employee of Biogen. Dr. Hughes has stock in Biogen.
Julius Eggebrecht (Roche Pharm AG) Julius Eggebrecht has received personal compensation for serving as an employee of Roche Pharma AG. Julius Eggebrecht has received stock or an ownership interest from Roche .
Petra Dirks Petra Dirks has received personal compensation for serving as an employee of F. Hoffmann-La Roche Ltd .
Stefanie Hieke-Schulz No disclosure on file
Klara Keine No disclosure on file
Tjalf Ziemssen, MD, FAAN (University Clinic Dresden) Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for BMS Celgene. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Sanofi. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for BMS Celgene. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for TEVA. The institution of Dr. Ziemssen has received research support from Biogen. The institution of Dr. Ziemssen has received research support from Novartis. The institution of Dr. Ziemssen has received research support from Merck. The institution of Dr. Ziemssen has received research support from Sanofi. The institution of Dr. Ziemssen has received research support from Celgene.